The Effect of Metformin and DPP4 Inhibitors on Cognition and Cardiovascular Protection in Type 2 Diabetic Patients


The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and cardiovascular protection in Type 2 Diabetic Patients

Full Title of Study: “The Impact of Metformin and Dipeptidyl Peptidase- 4 Inhibitors on Cognitive Function and Cardiovascular Protection in Type 2 Diabetic Patients”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: September 2022

Detailed Description

This study aims to investigate the effect of daily oral DPP4 inhibitors and oral metformin on neurodegeneration in type 2 diabetic patients. This study aims to compare between the cardiovascular protective properties of DPP-4 inhibitors and Metformin in type 2 diabetic patients.


  • Drug: Vildagliptin
    • observe the effect of vildagliptin on cognitive function and cardiovascular in diabetic patients

Arms, Groups and Cohorts

  • group 1
    • patients will be treated with DPP4 inhibitor + metformin
  • control
    • patients will be treated with metformin without DPP4 inhibitor.

Clinical Trial Outcome Measures

Primary Measures

  • improve the neurodegeneration and cardiovascular effect in diabetic patients
    • Time Frame: September 2022
    • improve the cognition and cardiovascular effect in type 2 diabetic patients

Participating in This Clinical Trial

Inclusion Criteria

  • Patient should be diagnosed with Type 2 diabetes mellitus (T2DM) and guided with HA1c ≥7, age ≥40 years. – moderate hypertension. Exclusion Criteria:

  • • Diabetic patients who have been currently receiving anti-diabetic agents other than metformin and/or insulin – Patients with type 1 DM, active liver disease, recent history of cardiovascular disease (acute coronary syndrome, coronary artery intervention, New York Heart Association Class III/IV heart failure, stroke, transient ischemic neurologic event, or new/worsening symptoms of coronary heart disease or cerebrovascular disease), severe peripheral vascular disease, triglyceride levels ≥ 600 mg/dL, history of HIV infection, pancreatitis, malignancy or clinically important hematologic disorder, and an estimated glomerular filtration rate (eGFR; calculated using the Modification of Diet in Renal Disease formula) less than 30 mL/min/1.73 m2. – Moreover, patients with dementia, AD, those were in delirium status during evaluation period, patients with psychotic disease (schizoaffective disorder, etc.) – Alcohol and substance addiction were not enrolled in the study. – Also, patients who have any hypersensitivity to metformin or to DPP4 inhibitors were also excluded.

Gender Eligibility: All

Minimum Age: 40 Years

Maximum Age: 60 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • MTI University
  • Collaborator
    • National Institute of Diabetes and Endocrinology, Egypt
  • Provider of Information About this Clinical Study
    • Principal Investigator: Toka Hesham, Teaching assistant of Clinical Pharmacy – MTI University
  • Overall Official(s)
    • Toka Hesham, Principal Investigator, Bachelor of Pharmacy and Pharmaceutical sciences (Clinical Pharmacy)
  • Overall Contact(s)
    • Toka H Elemary, +01069155142,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.